The leading Severe Asthma Companies such as Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology ...

The probability of revision sinus surgery including removing nasal polyps is higher if the patient has asthma or is on ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

The U.S. Food and Drug Administration (FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with treatment ...

The authors reported a significant improvement in nasal polyps score (NPS), assessed as primary outcome; but secondary outcomes such as symptoms and olfactory function were also improved. Moreover, ...

Dr Erna said the 8-year-old student's blindness occurred suddenly at school, shocking their teacher and classmates. "Teacher, why can't I see anything?" the young child was said to have suddenly ...

The glasses have been tested by over 300 blind individuals from nearly 30 countries, with overwhelmingly positive feedback. Gutt recalls witnessing users walk independently without white canes for ...